Leptomeningeal Metastases

Cross-source consensus on Leptomeningeal Metastases from 1 sources and 5 claims.

1 sources · 5 claims

Risks & contraindications

Other

Highlighted claims

NSCLC patients with leptomeningeal metastases have poor quality of life and poor survival. — Safety and efficacy of intrathecal pemetrexed and bevacizumab in non-small cell lung cancer (NSCLC) patients with leptomeningeal metastases (LM): protocol for a single-arm, prospective, phase Ia trial
Leptomeningeal metastases are an increasingly important complication in non-small cell lung cancer because patients with lung cancer are surviving longer. — Safety and efficacy of intrathecal pemetrexed and bevacizumab in non-small cell lung cancer (NSCLC) patients with leptomeningeal metastases (LM): protocol for a single-arm, prospective, phase Ia trial
Reported leptomeningeal metastasis incidence in NSCLC is 3% to 5%, with higher rates in EGFR-mutated or ALK-rearranged tumours. — Safety and efficacy of intrathecal pemetrexed and bevacizumab in non-small cell lung cancer (NSCLC) patients with leptomeningeal metastases (LM): protocol for a single-arm, prospective, phase Ia trial
Median overall survival for NSCLC patients with leptomeningeal metastases is reported at 3.6 to 11 months. — Safety and efficacy of intrathecal pemetrexed and bevacizumab in non-small cell lung cancer (NSCLC) patients with leptomeningeal metastases (LM): protocol for a single-arm, prospective, phase Ia trial
Positive CSF cytology is considered the diagnostic gold standard for leptomeningeal metastases, but its first-test sensitivity is low. — Safety and efficacy of intrathecal pemetrexed and bevacizumab in non-small cell lung cancer (NSCLC) patients with leptomeningeal metastases (LM): protocol for a single-arm, prospective, phase Ia trial